Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group. - Wikidata - wikimedia - TriplyDB

Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group.

Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group.

http://www.wikidata.org/entity/Q42984083

about

Identification of a lactoferrin-derived peptide possessing binding activity to hepatitis C virus E2 envelope protein High versus standard doses interferon-alpha in the treatment of naïve chronic hepatitis C patients in Taiwan: a 10-year cohort study Interferon responsiveness in patients infected with hepatitis C virus 1b differs depending on viral subtype IgG1 anti-P2 as a marker of response to interferon in patients with chronic hepatitis C GB Virus C/Hepatitis G Virus (GBV-C/HGV): still looking for a disease High serum leptin is an independent risk factor for non-response patients with low viremia to antiviral treatment in chronic hepatitis C.Methodological issues in papers on IFN therapy: time for reappraisal.Long-term effects of interferon therapy on histology and development of hepatocellular carcinoma in hepatitis C.Molecular techniques for clinical diagnostic virology Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection.Mutations in the E2-PePHD region of hepatitis C virus genotype-3a and correlation with response to interferon and ribavirin combination therapy in Pakistani patients Chemoprevention of hepatocellular carcinoma: concept, progress and perspectives.New combination test for hepatitis C virus genotype and viral load determination using Amplicor GT HCV MONITOR test v2.0.Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy.Pharmacogenomic perspectives of chronic hepatitis C virus (HCV) infection.Viral etiology of hepatocellular carcinoma and HCV genotypes in Taiwan.A randomized trial of 24 versus 48 weeks of peginterferon α-2a in patients infected with chronic hepatitis C virus genotype 2 or low viral load genotype 1: a multicenter national study in Japan.Performance of the COBAS AMPLICOR HCV MONITOR test, version 2.0, an automated reverse transcription-PCR quantitative system for hepatitis C virus load determination.Case selection for interferon treatment of hepatitis C.Sustained virologic response achieved after curative treatment of hepatitis C virus-related hepatocellular carcinoma as an independent prognostic factor.Soluble adhesion molecules correlate with liver inflammation and fibrosis in chronic hepatitis C treated with interferon-alpha.Interferon therapy for 2 years or longer reduces the incidence of hepatocarcinogenesis in patients with chronic hepatitis C viral infection.Early hepatitis C virus changes and sustained response in patients with chronic hepatitis C treated with peginterferon alpha-2b and ribavirin.Automation of polymerase chain reaction-based systems for detection of hepatitis C virus RNA.Prediction of efficacy of interferon treatment of chronic hepatitis C and occurrence of HCC after interferon treatment by a new classification.Amino acid substitutions in NS5A region of GB virus C and response to interferon therapy.Quantification of hepatitis C virus by TaqMan PCR: comparison with HCV Amplicor Monitor assay.High-dose natural interferon-alpha therapy for chronic hepatitis C with a high viral load: predictors of efficacy. The Aomori, Akita and Iwate Areas Viral Hepatitis Research Group.Evaluation of clinical usefulness of second-generation HCV core antigen assay: comparison with COBAS AMPLICOR HCV MONITOR assay version 2.0.Efficacy of interferon therapy in elderly patients with chronic hepatitis C.Efficacy and cost-effectiveness of consensus interferon monotherapy with high-dose induction for hepatitis C patients with genotype 2.Clinical characteristics of patients with chronic hepatitis C showing biochemical remission, without hepatitis C virus eradication, as a result of interferon therapy. The Osaka Liver Disease Study Group.Prolonged negative HCV-RNA status led to a good outcome in chronic hepatitis C patients with genotype 1b and super-high viral load.2'-,5'-Oligoadenylate synthetase response ratio predicting virological response to PEG-interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C.Immunological response to interferon-gamma priming prior to interferon-alpha treatment in refractory chronic hepatitis C in relation to viral clearance.Evaluation of the clinical usefulness of COBAS AMPLICOR HCV MONITOR assay (ver2.0): Comparison with AMPLICOR HCV MONITOR assay (ver1.0) and HCV core protein level.Mutations in ISDR of NS5A gene influence interferon efficacy in Chinese patients with chronic hepatitis C virus genotype 1b infection.Intrahepatic MxA and PKR protein expression in chronic hepatitis C virus infection.Long-term histological prognosis and serum fibrosis markers in chronic hepatitis C patients treated with interferon.Perihepatic lymph node enlargement is a negative predictor for sustained responses to pegylated interferon-α and ribavirin therapy for Japanese patients infected with hepatitis C virus genotype 1.

P2860

Q24338469-041516E2-1B88-4C95-B2E2-2F8105FA1E7D Q24799492-2F78FF1A-C7D5-4B46-8151-9313AA84D352 Q27477854-E18C81C1-E0E1-4EF5-93C0-52AB8020D88D Q27480600-D6E43776-FB43-41CD-BEB8-20C48BB088C0 Q27486644-62928BB2-EAA2-4380-804E-F5DD32550A78 Q33788303-BAEC23FD-8619-4203-931C-83427BE5EE19 Q33940500-2533BD33-9404-47AB-9008-2022C99BF8CD Q33988105-D5D77A5E-5771-4E09-8DB1-12CD94E67929 Q34015058-8CCF5D50-1975-4894-A841-7A0B8869FFD4 Q34129547-43E01190-8786-498D-98F0-8E87E02998D0 Q34481770-2E33829E-304E-40F6-8A6C-6E2A4093DBD3 Q34536138-932B79D2-AA6B-42BD-9A47-959195687E33 Q34605687-FD72F3EE-7898-4CEA-B1B1-7BAC3902B2CF Q34621423-5002C594-AE92-495C-A1AA-811D4404FF6E Q35740155-30B8F399-3001-4F50-AD5A-A3E0762184C6 Q36258740-FC187184-03F1-4AD7-959B-BEDC3B1A752D Q37356788-4C63B7BB-D0AC-4C08-A067-4BBF122CB7E2 Q39458171-24C5A072-BCC0-43C0-9740-0316FE41BEAA Q40755017-84A2AE8D-5235-4232-ABE6-03F4AA86FD28 Q42164795-58E66DC3-258D-4927-B1F0-F68F31D831A8 Q42465048-0E07130B-DA26-45EA-930D-628C6741BD52 Q42989123-173ED292-8FA3-46F9-BC13-5CF4418BC481 Q42990511-35F4C586-D7A7-4928-8018-A29EEB5422BE Q42990741-C9FA96F1-28BD-4DA0-A307-60FBCCD16F16 Q42991466-A1248D38-9668-4E8B-939D-C0DA50B66FF7 Q42992697-E3B99E6B-16AE-43B8-B932-B70B9A6965F0 Q42993577-2004D47B-087E-446C-9783-F5F256221EFE Q42994590-170F0DEA-15B1-4325-8B04-CD3F8A2D058E Q42997080-CD1675D0-1391-47F1-98D5-035B1871D3C3 Q42997762-2F8A1326-8D96-4503-A99A-4B0B8465A75E Q42999698-04659713-592A-416D-AB7F-15D7F0689D51 Q43000078-FF4B8153-7FFB-43BF-A2E6-A447493B099D Q43030767-27C57988-673F-4019-A15B-EF6E2E9B41EC Q43031195-3D50201E-835D-442D-B9DF-842B805B5691 Q43031802-2B64D1B8-FE76-4AF6-B805-78ACF639ABBE Q43040005-F8B73CF1-3C99-49C3-B6BA-F9652DF2F5A3 Q43041166-8CDCCD39-0C3D-4D41-950E-F7A3B14955B1 Q43527754-3B0AE04D-FCD7-4F0A-B556-67DEDAFCA332 Q43762372-5097C3FA-A184-4BBF-93DE-D3C22E4F4ABB Q45209851-45E5088E-07EE-4727-91EE-62D9B150403F

P2860

Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group.

http://www.wikidata.org/entity/Q42984083

description

1997 nî lūn-bûn

@nan

1997年の論文

@ja

1997年論文

@yue

1997年論文

@zh-hant

1997年論文

@zh-hk

1997年論文

@zh-mo

1997年論文

@zh-tw

1997年论文

@wuu

1997年论文

@zh

1997年论文

@zh-cn

name

Predictors of the efficacy of ...... hiba Hepatitis Research Group.

@en

Predictors of the efficacy of ...... hiba Hepatitis Research Group.

@nl

type

label

Predictors of the efficacy of ...... hiba Hepatitis Research Group.

@en

Predictors of the efficacy of ...... hiba Hepatitis Research Group.

@nl

prefLabel

Predictors of the efficacy of ...... hiba Hepatitis Research Group.

@en

Predictors of the efficacy of ...... hiba Hepatitis Research Group.

@nl

P1433

Q42984083-E20FF8C0-0C74-43BB-A0F6-A5435B00C98A

P1476

Q42984083-83A22DF8-2B5C-4E88-812C-68A7EC1F3424

P2093

Q42984083-070A84F1-9C5D-482A-9013-0D1B9DAE6A89

Q42984083-41926D53-4619-4672-9F46-18BFAD66DD67

Q42984083-42E096EC-AB14-41EC-A8B8-943F942769E9

Q42984083-4E195FCB-288E-41F6-8CCB-26F2424CC883

Q42984083-73ED12AE-567C-427D-9E29-157A716B8FBB

Q42984083-7503A55B-C867-481B-8E03-1B73CB414CE5

Q42984083-9FCD50DB-5EAF-48D8-ADC0-B786F603514B

Q42984083-C7EDE768-DE64-4D90-B2F2-CBDFF55C3931

Q42984083-CB39B3C8-85BF-4BDA-B1CF-D56023464122

Q42984083-D75F58E4-157E-40B8-9E2A-1DCC486831A1

P304

Q42984083-DE9C3DD0-F101-4A26-97B1-F8A44A4F6E4D

P31

Q42984083-20E8A090-964D-43C1-AE19-05127BBC2E57

P356

Q42984083-15D52F01-B664-419D-8672-25421E6471BD

P407

Q42984083-82384007-1362-4626-9562-C53554D74B85

P433

Q42984083-4ACE712E-11BE-4466-ADFD-05882AD485E6

P478

Q42984083-3FE47624-A712-4368-BEC0-91FED1BED55B

P577

Q42984083-42E86D98-E1A2-4A0A-B9AC-DA736E6D6036

P698

Q42984083-FB5C5296-2438-4181-910C-A693D0EEB881

P356

GAST.1997.V113.PM9247476

P1433

Gastroenterology

P1476

Predictors of the efficacy of ...... hiba Hepatitis Research Group.

@en

P2093

Arakawa Y

http://www.w3.org/2001/XMLSchema#string

Asada M

http://www.w3.org/2001/XMLSchema#string

Hashimoto E

http://www.w3.org/2001/XMLSchema#string

Hayashi N

http://www.w3.org/2001/XMLSchema#string

Imazeki F

http://www.w3.org/2001/XMLSchema#string

Kato N

http://www.w3.org/2001/XMLSchema#string

Kuroda H

http://www.w3.org/2001/XMLSchema#string

Nakamura A

http://www.w3.org/2001/XMLSchema#string

Omata M

http://www.w3.org/2001/XMLSchema#string

Shiratori Y

http://www.w3.org/2001/XMLSchema#string

P304

558-566

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1053/GAST.1997.V113.PM9247476

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

113

http://www.w3.org/2001/XMLSchema#string

P577

1997-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

9247476

http://www.w3.org/2001/XMLSchema#string